{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:01:07Z","timestamp":1753437667176},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Colombiana de Psiquiatr\u00eda"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.rcp.2015.05.013","type":"journal-article","created":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T12:20:49Z","timestamp":1436098849000},"page":"67-74","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Costo efectividad de los antipsic\u00f3ticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia"],"prefix":"10.1016","volume":"45","author":[{"given":"Hoover","family":"Quitian Reyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jair Alberto","family":"Arciniegas Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Boh\u00f3rquez Pe\u00f1aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"G\u00f3mez Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcp.2015.05.013_bib0315","first-page":"815315","article-title":"Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence","volume":"2012","author":"Bartholomeusz","year":"2012","journal-title":"Schizophr Res Treat."},{"year":"2010","series-title":"Britain) NCC for MH (Great. Schizophrenia: the NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secundary care","key":"10.1016\/j.rcp.2015.05.013_bib0320"},{"issue":"6195","key":"10.1016\/j.rcp.2015.05.013_bib0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/336095a0","article-title":"Where next with psychiatric illness?","volume":"336","year":"1988","journal-title":"Nature."},{"key":"10.1016\/j.rcp.2015.05.013_bib0330","first-page":"409205","article-title":"Factor structure of social cognition in schizophrenia: is empathy preserved?","volume":"2013","author":"Corbera","year":"2013","journal-title":"Schizophr Res Treat."},{"key":"10.1016\/j.rcp.2015.05.013_bib0335","article-title":"Social cognition and work performance of persons with schizophrenia in a Chinese population","author":"Lo","year":"2014","journal-title":"Work Read Mass."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0340","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10198-006-0347-0","article-title":"A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany","volume":"7","author":"Beard","year":"2006","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care."},{"key":"10.1016\/j.rcp.2015.05.013_bib0345","series-title":"Schizophrenia [Internet]","first-page":"413","article-title":"Economics of Schizophrenia: A Review","author":"Knapp","year":"2003"},{"issue":"6","key":"10.1016\/j.rcp.2015.05.013_bib0350","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s004060070002","article-title":"Epidemiology of schizophrenia: the global burden of disease and disability","volume":"250","author":"Jablensky","year":"2000","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"10.1016\/j.rcp.2015.05.013_bib0355","unstructured":"Rodr\u00edgues J, Acosta N, Enrique R. CARGA DE ENFERMEDAD COLOMBIA 2005 [Internet]. Bogot\u00e1, Colombia: Pontificia Universidad Javeriana - Centro de proyectos para el desarrollo CENDEX; 2008 Oct. Available from: http:\/\/www.cendex.org.co\/GPES\/informes\/PresentacionCarga_Informe.pdf."},{"issue":"2 Suppl","key":"10.1016\/j.rcp.2015.05.013_bib0360","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry."},{"issue":"9831","key":"10.1016\/j.rcp.2015.05.013_bib0365","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0370","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Mol Psychiatry."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.013_bib0375","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr Scand."},{"issue":"9618","key":"10.1016\/j.rcp.2015.05.013_bib0380","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.rcp.2015.05.013_bib0385","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.rcp.2015.05.013_bib0390","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.rcp.2015.05.013_bib0395","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"2","author":"Khanna","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"issue":"Suppl 18","key":"10.1016\/j.rcp.2015.05.013_bib0400","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"J Clin Psychiatry."},{"issue":"12","key":"10.1016\/j.rcp.2015.05.013_bib0405","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0410","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol Psychiatry."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.013_bib0415","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0420","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jval.2011.08.1741","article-title":"Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia","volume":"15","author":"Graham","year":"2012","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"issue":"2 Suppl 1","key":"10.1016\/j.rcp.2015.05.013_bib0425","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","article-title":"Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia","volume":"28","author":"Kane","year":"2008","journal-title":"J Clin Psychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.rcp.2015.05.013_bib0430","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/S0034-89102009000800010","article-title":"Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System","volume":"43","author":"Lindner","year":"2009","journal-title":"Rev Sa\u00fade P\u00fablica."},{"issue":"Suppl 1","key":"10.1016\/j.rcp.2015.05.013_bib0435","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00019053-200523001-00007","article-title":"Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA","volume":"23","author":"Edwards","year":"2005","journal-title":"PharmacoEconomics."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0440","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.013_bib0445","first-page":"220","article-title":"Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol","volume":"25","author":"De Sena","year":"2003","journal-title":"Rev Bras Psiquiatr S\u00e3o Paulo Braz 1999"},{"issue":"11","key":"10.1016\/j.rcp.2015.05.013_bib0450","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4088\/JCP.v68n1116","article-title":"Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia","volume":"68","author":"Gaebel","year":"2007","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophr Res."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004850-200501000-00007","article-title":"Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure","volume":"20","author":"Sacchetti","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0465","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00019053-200523030-00009","article-title":"Cost-effectiveness model of long-acting risperidone in schizophrenia in the US","volume":"23","author":"Edwards","year":"2005","journal-title":"PharmacoEconomics."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.013_bib0470","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3111\/13696998.2012.681531","article-title":"Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden","volume":"15","author":"Mehnert","year":"2012","journal-title":"J Med Econ."},{"key":"10.1016\/j.rcp.2015.05.013_bib0475","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-12-26","article-title":"A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia","volume":"12","author":"Coppola","year":"2012","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rcp.2015.05.013_bib0480","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0485","first-page":"e385","article-title":"A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia","volume":"15","author":"Cooper","year":"2008","journal-title":"Can J Clin Pharmacol J Can Pharmacol Clin."},{"issue":"10","key":"10.1016\/j.rcp.2015.05.013_bib0490","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"J Clin Psychiatry."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.013_bib0495","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J Clin Psychopharmacol."},{"issue":"7","key":"10.1016\/j.rcp.2015.05.013_bib0500","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.013_bib0505","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2015.05.013_bib0510","first-page":"1","article-title":"Diabetes en Colombia: costos asociados con su cuidado","author":"Diana Tamayo","year":"2013","journal-title":"Obs Diabetes Colomb."},{"issue":"20","key":"10.1016\/j.rcp.2015.05.013_bib0515","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.rcp.2015.05.013_bib0520","first-page":"382","article-title":"M\u00e9todos para la Evaluaci\u00f3n Econ\u00f3mica de Los Programas de Asistencia Sanitaria","author":"Drummond","year":"2001","journal-title":"Ediciones D\u00edaz de Santos"},{"issue":"12","key":"10.1016\/j.rcp.2015.05.013_bib0525","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2165\/11537300-000000000-00000","article-title":"A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States","volume":"28","author":"Mavranezouli","year":"2010","journal-title":"PHARMACOECONOMICS."},{"journal-title":"Ministerio de la Protecci\u00f3n Social de Colombia","article-title":"Ministerio de la Protecci\u00f3n Social de, Colombia., Gu\u00eda Metodol\u00f3gica para la elaboraci\u00f3n de Gu\u00edas Atenci\u00f3n Integral en el Sistema General de Seguridad Social en Salud, Colombiano","year":"2010","key":"10.1016\/j.rcp.2015.05.013_bib0530"},{"issue":"4","key":"10.1016\/j.rcp.2015.05.013_bib0535","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2753.2009.01189.x","article-title":"Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis","volume":"16","author":"McIntyre","year":"2010","journal-title":"J Eval Clin Pract."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0540","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3111\/13696998.2012.662923","article-title":"Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States","volume":"15","author":"Ascher-Svanum","year":"2012","journal-title":"J Med Econ."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.013_bib0545","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1524-4733.2007.00280.x","article-title":"A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine","volume":"11","author":"Davies","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"issue":"7","key":"10.1016\/j.rcp.2015.05.013_bib0550","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1524-4733.2008.00344.x","article-title":"The cost-effectiveness of atypicals in the UK","volume":"11","author":"Heeg","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.013_bib0555","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1185\/03007995.2011.554533","article-title":"Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model","volume":"27","author":"Furiak","year":"2011","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0447.2011.01716.x","article-title":"Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder","volume":"124","author":"Kasteng","year":"2011","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rcp.2015.05.013_bib0565","unstructured":"Banco de la Rep\u00fablica de Colombia. PIB total y por habitante [Internet]. 2014 [cited 2014 Jan 23]. Available from: http:\/\/www.banrep.gov.co\/es\/pib."},{"key":"10.1016\/j.rcp.2015.05.013_bib0570","unstructured":"NICE. CG82 Schizophrenia (update): full guideline [Internet]. NICE. [cited 2013 May 3]. Available from: http:\/\/www.nice.org.uk\/."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.013_bib0575","first-page":"259","article-title":"Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS)","volume":"35","author":"Bernardo","year":"2007","journal-title":"Actas Esp Psiquiatr."},{"issue":"11","key":"10.1016\/j.rcp.2015.05.013_bib0580","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1185\/03007990802507547","article-title":"Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK","volume":"24","author":"Davies","year":"2008","journal-title":"Curr Med Res Opin."},{"issue":"Suppl","key":"10.1016\/j.rcp.2015.05.013_bib0585","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0920-9964(98)00168-6","article-title":"Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia","volume":"35","author":"Revicki","year":"1999","journal-title":"Schizophr Res."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00019053-200927010-00007","article-title":"Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach","volume":"27","author":"De Ridder","year":"2009","journal-title":"PharmacoEconomics."},{"issue":"2","key":"10.1016\/j.rcp.2015.05.013_bib0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/026988110201600208","article-title":"The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study","volume":"16","author":"Hayhurst","year":"2002","journal-title":"J Psychopharmacol Oxf Engl."},{"issue":"6","key":"10.1016\/j.rcp.2015.05.013_bib0600","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0188-4409(02)00409-5","article-title":"A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia","volume":"33","author":"Palmer","year":"2002","journal-title":"Arch Med Res."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0605","first-page":"345","article-title":"A cost-effectiveness clinical decision analysis model for schizophrenia","volume":"4","author":"Palmer","year":"1998","journal-title":"Am J Manag Care."},{"issue":"10","key":"10.1016\/j.rcp.2015.05.013_bib0610","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archpsyc.1996.01830100104013","article-title":"Cost-effectiveness of clozapine monitoring after the first 6 months","volume":"53","author":"Zhang","year":"1996","journal-title":"Arch Gen Psychiatry."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.013_bib0615","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1185\/03007995.2010.537594","article-title":"Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia","volume":"27","author":"Ascher-Svanum","year":"2011","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.013_bib0620","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2753.2006.00782.x","article-title":"Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia","volume":"13","author":"Bounthavong","year":"2007","journal-title":"J Eval Clin Pract."}],"container-title":["Revista Colombiana de Psiquiatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745015000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745015000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T20:40:46Z","timestamp":1566938446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034745015000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0034745015000761"],"URL":"https:\/\/doi.org\/10.1016\/j.rcp.2015.05.013","relation":{},"ISSN":["0034-7450"],"issn-type":[{"type":"print","value":"0034-7450"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Costo efectividad de los antipsic\u00f3ticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia","name":"articletitle","label":"Article Title"},{"value":"Revista Colombiana de Psiquiatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcp.2015.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 Asociaci\u00f3n Colombiana de Psiquiatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}